Literature DB >> 21963838

Differential effects of eNOS uncoupling on conduit and small arteries in GTP-cyclohydrolase I-deficient hph-1 mice.

Livius V d'Uscio1, Leslie A Smith, Zvonimir S Katusic.   

Abstract

In the present study, we used the hph-1 mouse, which displays GTP-cyclohydrolase I (GTPCH I) deficiency, to test the hypothesis that loss of tetrahydrobiopterin (BH(4)) in conduit and small arteries activates compensatory mechanisms designed to protect vascular wall from oxidative stress induced by uncoupling of endothelial nitric oxide synthase (eNOS). Both GTPCH I activity and BH(4) levels were reduced in the aortas and small mesenteric arteries of hph-1 mice. However, the BH(4)-to-7,8-dihydrobiopterin ratio was significantly reduced only in hph-1 aortas. Furthermore, superoxide anion and 3-nitrotyrosine production were significantly enhanced in aortas but not in small mesenteric arteries of hph-1 mice. In contrast to the aorta, protein expression of copper- and zinc-containing superoxide dismutase (CuZnSOD) was significantly increased in small mesenteric arteries of hph-1 mice. Protein expression of catalase was increased in both aortas and small mesenteric arteries of hph-1 mice. Further analysis of endothelial nitric oxide synthase (eNOS)/cyclic guanosine monophosphate (cGMP) signaling demonstrated that protein expression of phosphorylated Ser(1177)-eNOS as well as basal cGMP levels and hydrogen peroxide was increased in hph-1 aortas. Increased production of hydrogen peroxide in hph-1 mice aortas appears to be the most likely mechanism responsible for phosphorylation of eNOS and elevation of cGMP. In contrast, upregulation of CuZnSOD and catalase in resistance arteries is sufficient to protect vascular tissue from increased production of reactive oxygen species generated by uncoupling of eNOS. The results of our study suggest that anatomical origin determines the ability of vessel wall to cope with oxidative stress induced by uncoupling of eNOS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21963838      PMCID: PMC3233811          DOI: 10.1152/ajpheart.00588.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  50 in total

Review 1.  Targeting endothelial and myocardial dysfunction with tetrahydrobiopterin.

Authors:  An L Moens; Rinrada Kietadisorn; Judy Y Lin; David Kass
Journal:  J Mol Cell Cardiol       Date:  2011-03-31       Impact factor: 5.000

2.  Erythropoietin increases expression and function of vascular copper- and zinc-containing superoxide dismutase.

Authors:  Livius V d'Uscio; Leslie A Smith; Zvonimir S Katusic
Journal:  Hypertension       Date:  2010-03-01       Impact factor: 10.190

3.  The ratio between tetrahydrobiopterin and oxidized tetrahydrobiopterin analogues controls superoxide release from endothelial nitric oxide synthase: an EPR spin trapping study.

Authors:  Jeannette Vásquez-Vivar; Pavel Martásek; Jennifer Whitsett; Joy Joseph; Balaraman Kalyanaraman
Journal:  Biochem J       Date:  2002-03-15       Impact factor: 3.857

4.  Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk.

Authors:  Lian Zhang; Fangwen Rao; Kuixing Zhang; Srikrishna Khandrika; Madhusudan Das; Sucheta M Vaingankar; Xuping Bao; Brinda K Rana; Douglas W Smith; Jennifer Wessel; Rany M Salem; Juan L Rodriguez-Flores; Sushil K Mahata; Nicholas J Schork; Michael G Ziegler; Daniel T O'Connor
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

5.  Tetrahydrobiopterin recycling, a key determinant of endothelial nitric-oxide synthase-dependent signaling pathways in cultured vascular endothelial cells.

Authors:  Toru Sugiyama; Bruce D Levy; Thomas Michel
Journal:  J Biol Chem       Date:  2009-03-12       Impact factor: 5.157

Review 6.  Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects.

Authors:  Zvonimir S Katusic; Livius V d'Uscio; Karl A Nath
Journal:  Trends Pharmacol Sci       Date:  2008-11-29       Impact factor: 14.819

7.  Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme.

Authors:  Chun-An Chen; Lawrence J Druhan; Saradhadevi Varadharaj; Yeong-Renn Chen; Jay L Zweier
Journal:  J Biol Chem       Date:  2008-07-13       Impact factor: 5.157

8.  AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats.

Authors:  Philip Wenzel; Eberhard Schulz; Matthias Oelze; Johanna Müller; Swenja Schuhmacher; Mohamed S S Alhamdani; Johannes Debrezion; Marcus Hortmann; Kurt Reifenberg; Ingrid Fleming; Thomas Münzel; Andreas Daiber
Journal:  Free Radic Biol Med       Date:  2008-05-23       Impact factor: 7.376

9.  Congenic mapping and genotyping of the tetrahydrobiopterin-deficient hph-1 mouse.

Authors:  Jeffrey P Khoo; Taija Nicoli; Nicholas J Alp; Janice Fullerton; Jonathan Flint; Keith M Channon
Journal:  Mol Genet Metab       Date:  2004-07       Impact factor: 4.797

10.  Ratio of 5,6,7,8-tetrahydrobiopterin to 7,8-dihydrobiopterin in endothelial cells determines glucose-elicited changes in NO vs. superoxide production by eNOS.

Authors:  Mark J Crabtree; Caroline L Smith; George Lam; Michael S Goligorsky; Steven S Gross
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-01-11       Impact factor: 4.733

View more
  14 in total

1.  Endothelium-specific amyloid precursor protein deficiency causes endothelial dysfunction in cerebral arteries.

Authors:  Livius V d'Uscio; Tongrong He; Anantha V Santhanam; Zvonimir S Katusic
Journal:  J Cereb Blood Flow Metab       Date:  2017-09-29       Impact factor: 6.200

Review 2.  Expression and Processing of Amyloid Precursor Protein in Vascular Endothelium.

Authors:  Livius V d'Uscio; Tongrong He; Zvonimir S Katusic
Journal:  Physiology (Bethesda)       Date:  2017-01

3.  Erythropoietin increases bioavailability of tetrahydrobiopterin and protects cerebral microvasculature against oxidative stress induced by eNOS uncoupling.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Zvonimir S Katusic
Journal:  J Neurochem       Date:  2014-08-06       Impact factor: 5.372

4.  Increased production of superoxide anion contributes to dysfunction of the arteriovenous fistula.

Authors:  Mykola V Tsapenko; Livius V d'Uscio; Joseph P Grande; Anthony J Croatt; Melissa C Hernandez; Allan W Ackerman; Zvonimir S Katusic; Karl A Nath
Journal:  Am J Physiol Renal Physiol       Date:  2012-09-19

5.  Uncoupling of endothelial nitric oxide synthase in cerebral vasculature of Tg2576 mice.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Tongrong He; Pritam Das; Steven G Younkin; Zvonimir S Katusic
Journal:  J Neurochem       Date:  2015-07-15       Impact factor: 5.372

6.  Uncoupling of eNOS causes superoxide anion production and impairs NO signaling in the cerebral microvessels of hph-1 mice.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Leslie A Smith; Zvonimir S Katusic
Journal:  J Neurochem       Date:  2012-08-03       Impact factor: 5.372

7.  Vascular phenotype of amyloid precursor protein-deficient mice.

Authors:  Livius V d'Uscio; Zvonimir S Katusic
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-22       Impact factor: 4.733

8.  Erythropoietin prevents endothelial dysfunction in GTP-cyclohydrolase I-deficient hph1 mice.

Authors:  Livius V dʼUscio; Anantha V R Santhanam; Zvonimir S Katusic
Journal:  J Cardiovasc Pharmacol       Date:  2014-12       Impact factor: 3.105

9.  Activation of PPARδ prevents endothelial dysfunction induced by overexpression of amyloid-β precursor protein.

Authors:  Livius V d'Uscio; Pritam Das; Anantha V R Santhanam; Tongrong He; Steven G Younkin; Zvonimir S Katusic
Journal:  Cardiovasc Res       Date:  2012-08-10       Impact factor: 10.787

10.  PPARδ agonist GW501516 prevents uncoupling of endothelial nitric oxide synthase in cerebral microvessels of hph-1 mice.

Authors:  Anantha Vijay R Santhanam; Livius V d'Uscio; Tongrong He; Zvonimir S Katusic
Journal:  Brain Res       Date:  2012-09-13       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.